Advanced search
Publication Cover
Expert Opinion on Emerging Drugs Volume 10, 2005 - Issue 3
Submit an article Journal homepage
79
Views
22
CrossRef citations to date
0
Altmetric
Review

Malaria vaccines in development

W Ripley Ballou GlaxoSmithKline Biologicals, Clinical Research and Development, and Research and Development, Rixensart, Belgium. [email protected]
Pages 489-503 | Published online: 05 Aug 2005

Bibliography

  • SNOW RW, GUERRA CA, NOOR AM et al.: The global distribution of clinical episodes of Plasmodium fakiparum malaria. Nature (2005) 434:214–217.
  • GARDNER MJ, HALL N, FUNG E et al.: Genome sequence of the human malaria parasite plasmodium falciparum. Nature (2002) 419:498–511.
  • BALLOU WR, KESTER KE, HEPPNER DG: Pre-erythrocytic malaria vaccines to prevent Plasmodium falciparum malaria. In: Malaria Immunology. P Perlmann, M Troye-Blomberg (Eds). Chem. Immunol. Basel, Karger, Switzerland (2002):253–261.
  • HOFFMAN SL, WISTAR R, BALLOU WR et al.: Immunity to malaria and naturally acquired antibodies to the circumsporozoite protein of Plasmodium falciparum. N EngL J. Med. (1986) 315:601–606.
  • PLEBANSKI M, AIDOO M, WHITTLE HC et al.: Precursor frequency analysis of cytotoxic T lymphocytes to pre-erythrocytic antigens of Plasmodium falciparum in west Africa. J. Immunol. (1997) 158:2849–2855.
  • SCHELLENBERG D, MENENDEZ C, KAHIGWA E et al.: African children with malaria in an area of intense Plasmodium falciparum transmission: features on admission to the hospital and risk factors for death. Am. J. Trop. Med. Hyg (1999) 61:431–438.
  • THOMAS AW, TRAPE JF, ROGIER C, GONCALVES A, ROSARIO VE, NARUM DL: High prevalence of natural antibodies against Plasmodium falciparum 83-kilodalton apical membrane antigen (PF83/AMA-1) as detected by capture-enzyme-linked immunosorbent assay using full-length baculovirus recombinant PF83/ AMA-1. Am. J. Trop. Med. Hyg (1994) 51(6):730–740.
  • GOOD MF: Vaccine-induced immunity to malaria parasites and the need for novel strategies. Trends Parasitol. (2005) 21:29–34.
  • BLACKMAN MJ, SCOTT-FINNIGAN TJ, SHAI S, HOLDER AA: Antibodies inhibit the protease-mediated processing of a malaria merozoite surface protein. J. Exp. Med. (1994) 180:389–393.
  • SCHOFIELD L, HEWITT MC, EVANS K et al.: Synthetic GPI as a candidate anti-toxic vaccine in a model of malaria. Nature (2002) 418:785–789.
  • KASLOW DC: Transmission-blocking vaccines. Chem. ImmunoL (2002) 80:287–307.
  • BALLOU WR, KESTER KE, STOUTE JA et al.: Malaria vaccines: triumphs or tribulations? Parasitologia (1999) 41(1-3):403–408.
  • NUSSENZWEIG RS, VANDERBERG J, MOST H, ORTON C: Protective immunity produced by the injection of X-irradiated sporozoites of Plasmodium berghei. Nature (1967) 216:160–162.
  • NUSSENZWEIG NUSSENZWEIG RS: Rationale for the development of an engineered sporozoite malaria vaccine. Adv. Immunol. (1989) 45:283–334.
  • CLYDE DF, MOST H, MCCARTHY VC, VANDERBERG JP: Immunization of man against sporozite-inducedfakiparum malaria. Am. J. Med. Sci. (1973) 266:169–177.
  • EGAN JE, WEBER JL, BALLOU WR et al.: Efficacy of murine malaria sporozoite vaccines: implications for human vaccine development. Science (1987) 236:453–456.
  • NARDIN EH, NUSSENZWEIG RS, ALTSZULER R et al.: Cellular and humoral immune responses to a recombinant Pfalciparum CS protein in sporozoite-immunized rodents and human volunteers. Bull. World Health Organ. (1990) 68:85–87.
  • EGAN JE, HOFFMAN SL, HAYNES JD et al.: Humoral immune responses in volunteers immunized with irradiated Plasmodium falciparum sporozoites. Am. J. Trop. Med. Hyg. (1993) 49:166–173.
  • KRZYCH U, LYON JL, JAREED T et al.: T lymphocytes from volunteers immunized with irradiated Pfakiparum sporozoites recognize liver and blood stage malaria antigens. J. ImmunoL (1995) 155:4072–4077.
  • HOFFMAN SL, GOH LM, LUKE TC et al.: Protection of humans against malaria by immunization with radiation attenuated Plasmodium species sporozoites. J. Infect. Dis. (2002) 185:1155–1164.
  • BEIER JC, BEIER MS, VAUGHAN JA, PUMPUNI CB, DAVIS JR, NODEN BH: Sporozoite transmission by Anopheles freeborni and Anopheles gambiae experimentally infected with Plasmodium falciparum. J. Am. Mosq. Control Assoc. (1992) 8:404–408.
  • SCHELLER LF, AZAD AF: Maintenance of protective immunity against malaria by persistent hepatic parasites derived from irradiated sporozoites. Proc. NatL Acad. Sci. USA (1995) 92:4066–4068.
  • BEJON P, ANDREWS L, ANDERSEN F et al.: Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites. J. Infect. Dis. (2005) 191:619–626.
  • BROWN AE, SINGHARAJ P, WEBSTER HK et al.: Safety, immunogenicity and limited efficacy study of a recombinant Plasmodium falciparum circumsporozoite vaccine in Thai soldiers. Vaccine (1994) 12:102–108.
  • SHERWOOD JA, COPELAND RS, TAYLOR KA et al.: Plasmodium falciparum circumsporozoite vaccine immunogencity and efficacy trial with natural challenge quantitation in an area of endemic human malaria of Kenya. Vaccine (1996) 14:817–827.
  • MOORTHY VS, IMOUKHUEDE EB, MILLIGAN P et al.: A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults. PLoS Med. (2004) 1:128–136.
  • KESTER KE, MCKINNEY DA, TORNIEPORTH N et al.: Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. J. Inf Dis. (2001) 183:640–647.
  • ALONSO PL, SACARLAL J, APONTE JJ et al.: Efficacy of the RTS,S/ASO2A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet (2004) 364:1411–1420.
  • SCHELLENBERG D, MENENDEZ C, KAHIGWA E et al.: Intermittent treatment for malaria and anaemia control at time of routine vaccination in Tanzanian infants; a randomised, placebo-controlled trial. Lancet (2001) 357:1471–1477.
  • MASSAGA JJ, KITUA AY, LEMNGE M et al.: Effect of intermittent treatment with amodiaquine on anaemia and malaria fevers in Tanzania; a randomised, placebo-controlled trial. Lancet (2003) 361:1853–1860.
  • LENGELER C: Insecticide-treated bed netsand curtains for preventing malaria. Cochrane Database Syst. Rev. (2004) 2:CD000363.
  • BALLOU WR, ROTHBARD J, WIRTZ RA et al.: Immunogenicity of synthetic peptides from the circumsporozoite protein of Plasmodium falciparum. Science (1985) 228:996–999.
  • RATHORE D, NAGARKATTI1 R, JANI D et al.: An immunologically cryptic epitope of Plasmodium fakiparum circumsporozoite protein facilitates liver cell recognition and induces protective antibodies that block liver cell invasion. Biol. Chem. (2005) 280(20:20524–20529.
  • REECE WH, PINDER M, GOTHARD PK et al.: A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease. Nat. Med. (2004) 10:406–410.
  • BERENZON D, SCHWENK RJ, LETELLIER L et al.: Protracted protection to plasmodium berghei malaria is linked to functionally and phenotypically heterogeneous liver memory CD8* T cells. ImmunoL (2003) 171:2024–2034.
  • CHULAY, JD, SCHNEIDER I, COSGRIFF TM et al.: Malaria transmitted to man by mosquitoes infected from cultured Plasmodium falciparum. Am. Soc. Trop. Med. Hyg. (1986) 35:66–68.
  • STOUTE JA., SLAOUI M, HEPPNER DG et al.: A preliminary evaluation of a recombinant circumsporozoite protein malaria vaccine against Plasmodium falciparum. N Engl. J. Med. (1997) 336:86–91.
  • BENMOHAMED L, THOMAS A, DRUILHE P: Long-term multiepitopic cytotoxic-T-lymphocyte responses induced in chimpanzees by combinations of Plasmodium falciparum liver-stage peptides and lipopeptides. Infect. Immun. (2004) 72:4376–4384.
  • VUOLA JM, KEATING S, WEBSTER DP et al.: Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers. J. Immunol. (2005) 174:449–455.
  • GORDON DM, MCGOVERN TW, KRZYCH U et al.: Safety, immunogenicity and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein/HBsAg subunit vaccine. J. Inf Dis. (1995) 171:1576–1585.
  • GARCON N, HEPPNER DG, COHEN J: Development of RTS,S/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant. Expert Rev. Vaccines (2003) 2:231–238.
  • SUN P, SCHWENK R, WHITE K et al.: Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4(*) and CD8(*) T cells producing IFN-gamma. J. Immunol (2003) 171(12):6961–6967.
  • LALVANI A, MORIS P, VOSS G et al.: Potent induction of focused Th-1 type cellular and humoral immune responses by RTS,S/SBAS2 recombinant Pfaktparum malaria vaccine. J. Infect. Dis. (1999) 180:1656–1664.
  • STOUTE, JA, KESTER KE, KRZYCH U et al.: Long term efficacy and immune responses following immunization with the RTS,S malaria vaccine. J. Infect. Dis.(1998) 178: 1139–1144.
  • DOHERTY JF, PINDER M, TORNIEPORTH N et al.: A Phase I safety and immunogenicity trial with the candidate malaria vaccine, RTS,S/SABAS2, in semi-immune adults in the Gambia. Am. J. Trop. Med. Hyg-. (1999) 61:865–868.
  • PINDER M, REECE WH, PLEBANSKI M et al.: Cellular immunity induced by the recombinant Plasmodium falciparum malaria vaccine, RTS,S/AS02, in semi-immune adults in the Gambia. Clin. Exp. Immunol (2004) 135:286–293.
  • BOJANG KA, MILLIGAN PJ, PINDER M et al.: Efficacy of RTS,S/A502 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in the Gambia: a randomised trial. Lancet (2001) 358:1927–1934.
  • HEPPNER DG, CUMMINGS JF, OCKENHOUSE CF, KESTER KE, COHEN JD, BALLOU WR: Adjuvanted RTS,S and other protein-based pre-erythrocytic stage malaria vaccines. In: New Generation Vaccines, 3rd Ed MM Levine, JB Kaper, R Rappuoli, MA Liu, MF Good (Eds), Dekker, New York, USA (2004):851–860.
  • HEPPNER DG Jr, KESTER KE, OCKENHOUSE CF et al.: Towards an RTS,S-based, multi-stage, multi-antigen vaccine against faktparum malaria: progress at the Walter Reed Army Institute of Research. Vaccine (2005) 23:2243–2250.
  • BIRKETT A, LYONS K, SCHMIDT A et al.: A modified hepatitis B virus core particle containing multiple epitopes of the Plasmodium falciparum circumsporozoite protein provides a highly immunogenic malaria vaccine in preclinical analyses in rodent and primate hosts. Infect. Immun. (2002) 70(12):6860–6870.
  • MILICH DR, HUGHES J, JONES J, SALLBERG M, PHILLIPS TR: Conversion of poorly immunogenic malaria repeat sequences into a highly immunogenic vaccine candidate. Vaccine (2002) 20:771–778.
  • NARDIN EH, OLIVEIRA GA, CALVO-CALLE JM et al.: Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes. Infect. Immun. (2004) 72(11):6519–6527.
  • WALTHER M, DUNACHIE S, KEATING S et al.: Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720. Vaccine (2005) 23(7):857–864.
  • ANDERSON RJ, HANNAN CM, GILBERT SC et al.: Enhanced CD8* T cell immune responses and protection elicited against Plasmodium berghei malaria by prime boost immunization regimens using a novel attenuated fowlpox virus. J. Immunol (2004) 172:3094–3100.
  • MOORE AC, HILL AV: Progress in DNA-based heterologous prime-boost immunization strategies for malaria. Immunol Rev. (2004) 199:126–143.
  • WEBSTER DP, DUNACHIE S, VUOLA JM et al.: Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc. Nail Acad. Sci. USA (2005) 102:4836–4841.
  • MOORTHY VS, MCCONKEY S, ROBERTS M et al.: Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage Pfaktparum malaria in non-immune volunteers. Vaccine (2003) 21:2004–2011.
  • MCCONKEY SJ, MOORTHY V, WEBSTER D et at.: Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat. Med. (2003) 9:729–735.
  • BRUNA-ROMERO O, GONZALEZ-ASEGUINOLAZA G, HAFALLA JC, TSUJI M, NUSSENZWEIG RS: Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen. Proc. Nail Acad. Sci. USA (2001) 98:11491–11496.
  • BAROUCH DH, PAU MG, CUSTERS JH et al.: Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J. Immunol (2004) 172(10):6290–6297.
  • ROGGERO MA, WEILENMANN C, BONELO A et al.: Plasmodium falciparum CS C-terminal fragment: preclinical evaluation and Phase I clinical studies. Parasitologia (1999) 41:421–424.
  • LOPEZ JA, WEILENMAN C, AUDRAN R et al.: A synthetic malaria vaccine elicits a potent CD8* and CD4* T lymphocyte immune response in humans. Implications for vaccination strategies. Eur. J. Immunol (2001) 31:1989–1998.
  • PRATO S, MAXWELL T, PINZ A et al.: MHC class I-restricted exogenous presentation of a synthetic 102-mer malaria vaccine polypeptide. Eur. j Immunol (2005) 35:681–689.
  • SMOOKER P, RAINCZUK A, KENNEDY N, SPITHILL T: DNA vaccines and their application against parasites - promise, limitations and potential solutions. BiotechnoL Ann. Rev. (2004) 10:189–236.
  • WANG R, DOOLAN DL, LE TP et al.: Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science (1998) 282:476–480.
  • WANG R, EPSTEIN J, BARACEROS FM et al.: Induction of CD4(*) T cell-dependent CD8(*) Type 1 responses in humans by a malaria DNA vaccine. Proc. Natl Acad. St-LUSA (2001) 98:10817–10822.
  • BALLOU WR, AREVELO-HERRERA M, CARUCCI D et al.: Update on the clinical development of candidate malaria vaccines. Am. J. Trop. Med. Hyg-. (2004) 71:239–247.
  • KURTIS JD, HOLLINGDALE MR, LUTY AJ, LANAR DE, KRZYCH U, DUFFY PE: Pre-erythrocytic immunity to Plasmodium fakiparum: the case for an LSA-1 vaccine. Trends Parasitol. (2001) 17:219–223.
  • HILLIER CJ, WARE LA, BARBOSA A et al.: Process development and analysis of liver-stage antigen 1, a preerythrocyte-stage protein-based vaccine for Plasmodium falciparum. Infect. Immun. (2005) 73:2109–2115.
  • DAUBERSIES P, THOMAS AW, MILLET P et al.: Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3. Nat. Med. (2000) 6:1258–1263.
  • PERLAZA BL, ZAPATA C, VALENCIA AZ et al.: Immunogenicity and protective efficacy ofPlasmodium falciparum liver-stage Ag-3 in Aotus lemurinus griseimembra monkeys. Eur. J. Immunol (2003) 33:1321–1327.
  • MORENO R, JIANG L, MOEHLE K et al.: Exploiting conformationally constrained peptidomimetics and an efficient human-compatible delivery system in synthetic vaccine design. Chembiochem. (2001) 5:838–843.
  • PFEIFFER B, PEDUZZI E, MOEHLE K et al.: A virosome-mimotope approach to synthetic vaccine design and optimization: synthesis, conformation, and immune recognition of a potential malaria-vaccine candidate. Angew. Chem. Int. Ed. Engl. (2003) 42(21):2368–2371.
  • MAHANTY S, SAUL A, MILLER LH: Progress in the development of recombinant and synthetic blood-stage malaria vaccines. J. Exp. Biol. (2003) 206:3781–3788.
  • GOOD MF, XU H, WYKES M, ENGWERDA CR: Development and regulation of cell-mediated immune responses to the blood stages of malaria: implications for vaccine research. Ann. Rev. Immunol (2005) 23:69–99.
  • OEUVRAY C, BOUHAROUN-TAYOUN H, GRAS-MASSE H et al.: Merozoite surface protein-3: a malaria protein inducing antibodies that promote Plasmodium filciparum killing by cooperation with blood monocytes. Blood (1994) 84:1594–1602.
  • STRUIK SS, RILEY EM: Does malaria suffer from lack of memory? Immunol Rev. (2004) 201:268–290.
  • DIGGS CL, BALLOU WR, MILLER LH et al.: The major merozoite surface protein as a malaria vaccine target. Parasitol Today (1994) 9:300–302.
  • BLACKMAN MJ, HOLDER AA: Secondary processing of the Plasmodium falciparum merozoite surface protein-1 (MSP1) by a calcium-dependent membrane-bound serine protease: shedding of MSP133 as a noncovalently associated complex with other fragments of the MSP1. Mol Biochem. Parasitol (1992) 50:307–315.
  • CHITNIS CE, BLACKMAN MJ: Host cellinvasion by malaria parasites. Parasitol Today (2000) 10:411–415.
  • MILLER LH, ROBERTS T, SHAHABUDDIN M, MCCUTCHAN TF: Analysis of sequence diversity in the Plasmodium falciparum merozoite surface protein-1 (MSP-1). Mol Biochem. Parasitol (1993) 59:1–14.
  • MORGAN WD, BIRDSALL B, FRENKIEL TA et al.: Solution structure of an EGF module pair from the Plasmodium falciparum merozoite surface protein 1. Mol Biol. (1999) 289:113–122.
  • GUEVARA-PATINO JA, HOLDER AA, MCBRIDE JS, BLACKMAN MJ: Antibodies that inhibit malaria merozoite surface protein-1 processing and erythrocyte invasion are blocked by naturally acquired human antibodies./ Exp. Med. (1999) 186:1689–1699.
  • KUMAR S, YADAVA A. KEISTER DB et al.: Immunogenicity and in vivo efficacy of recombinant Plasmodium falciparum merozoite surface protein-1 in Aotus monkeys. Mo/. Med. (1995) 1:332.
  • LEE EA, PALMER DR, FLANAGAN KL et al.: Induction of T helper Type 1 and 2 responses to 19-kilodalton merozoite surface protein 1 in vaccinated healthy volunteers and adults naturally exposed to malaria. Infect. Immun. (2002) 70(3):1417–1421.
  • ANGOV E, AUFERIO B TURGEON A et al.: Development and pre-clinical analysis of a Plasmodium falciparum merozoite surface protein-142 malaria vaccine. Mol Biochem. Parasitol (2003) 128:195–204.
  • PICHYANGKUL S, GETTAYACAMIN M, MILLERS et al.: Pre-clinical evaluation of the malaria vaccine candidate P falciparum MSP1-42 formulated with novel adjuvants or with alum. Vaccine (2004) 22:3831–3840.
  • DARKO CA, ANGOV E, COLLINS WE et al.: The clinical-grade 42-kilodalton fragment of merozoite surface protein 1 of Plasmodium filciparum strain FVO expressed in Escherichia coli protects Aotus nancymai against challenge with homologous erythrocytic-stage parasites. Infect. Immun. (2005) 73:287–297.
  • SINGH S, KENNEDY MC, LONG CA, SAUL AJ, MILLER LH, STOWERS AW: Biochemical and immunological characterization of bacterially expressed and refolded Plasmodium falciparum 42-kilodalton C-terminal merozoite surface protein 1. Infect. Immun. (2003) 71:6766–6774.
  • MILES AP, MCCLELLAN HC, RAUSCH KM et al.: Montanide® ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations. Vaccine (2005) 23:2528–2537.
  • PERRAUT R, MARRAMA L, DIOUF B et al.: Antibodies to the conserved C-terminal domain of the Plasmodium filciparum merozoite surface protein 1 and to the merozoite extract and their relationship with in vitro inhibitory antibodies and protection against clinical malaria in a Senegalese village. J. Infect. Dis. (2005) 191:264–271.
  • PERERA KL, HANDUNNETTI SM, HOLM I, LONGACRE S, MENDIS K: Baculovirus merozoite surface protein 1 C-terminal recombinant antigens are highly protective in a natural primate model for human Plasmodium vivax malaria. Infect. Immun. (1998) 66:1500–1506.
  • KEITEL W, KESTER KE, ATMAR R et al.: Phase I trial of two recombinant vaccines containing the 19kD carboxy terminal fragment of Plasmodium filciparum merozoite surface protein 1 (MSP-119) and T-helper epitopes of tetanus toxoid. Vaccine (1999) 18:531–539.
  • MILLER LH, BARUCH BI, MARSH K, DOUMBO OK: The pathogenic basis of malaria. Nature (2002) 415:673–679.
  • POLLEY SD, MWANGI T, KOCKEN CH et al.: Human antibodies to recombinant protein constructs of Plasmodium filciparum apical membrane antigen 1 (AMA1) and their associations with protection from malaria. Vaccine (2004) 23:718–728.
  • NARUM DL, THOMAS AW: Differential localization of full-length and processed forms of PF83/AMA-1, an apical membrane antigen of Plasmodium falciparum merozoites. MoL Biochem. ParasitoL (1984) 67:59–68.
  • BANNISTER LH, HOPKINS JM, DLUZEWSKI AR et al.: Plasmodium falciparum apical membrane antigen 1 (PfAMA-1) is translocated within micronemes along subpellicular microtubules during merozoite development. J. Cell Sci. (2003) 116:3825–3834.
  • SILVIE O, FRANETICH JF, CHARRIN S et al.: A role for apical membrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozoites. J. Biol. Chem. (2004) 279:9490–9496.
  • PIZARRO JC, VULLIEZ-LE NORMAND B, CHESNE-SECK ML et al.: Crystal structure of the malaria vaccine candidate apical membrane antigen 1. Science (2005) 308(5720):408–411.
  • DUTTA S, HAYNES JD, BARBOSA A et al.: Mode of action of invasion-inhibitory antibodies directed against apical membrane antigen 1 of Plasmodium fakiparum. Infect. Immun. (2005) 73:2116–2122.
  • CORTE A, MELLOMBO M, MASCIANTONIO R et al.: Allele specificity of naturally acquired antibody responses against Plasmodium falciparum apical membrane antigen 1. Infect. Immun. (2005) 73:422–430.
  • DUTTA S, LALITHA PV, WARE LA et al.: Purification, characterization, and immunogenicity of the refolded ectodomain of the Plasmodium falciparum apical membrane antigen 1 expressed in Escherichia coli. Infect. Immun. (2002) 70:3101–3110.
  • LALITHA PV WARE LA, BARBOSA A et al.: Production of the subdomains of the Plasmodium falciparum apical membrane antigen 1 ectodomain and analysis of the immune response. Infect. Immun. (2004) 72:4464–4470.
  • KENNEDY M, WANG J, ZHANG Y et al.: In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMAD: production and activity of an AMA1 vaccine and generation of a multiallelic response. Infect. Immun. (2002) 70:6948–6960.
  • STOWERS AW, KENNEDY MC, KEEGAN BP, SAUL A, LONG CA, MILLER LH: Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria. Infect. Immun. (2002) 70:6961–6967.
  • VULLIEZ-LE NORMAND B, PIZARRO JC, CHESNE-SECK ML et al.: Expression, crystallization and preliminary structural analysis of the ectoplasmic region of apical membrane antigen 1 from Plasmodium vivax, a malaria-vaccine candidate. Acta Crystallogr. D. Biol. Crystallogr. (2004) 60:2040–2043.
  • KOCKEN C, WITHERS-MARTINEZ C, DUBBELD M et al.: High-level expression of the malaria blood-stage vaccine candidate Plasmodium falciparum apical membrane antigen 1 and induction of antibodies that inhibit erythrocyte invasion. Infect. Immun. (2002) 70:4471–4476.
  • PAN W, HUANG D, ZHANG Q et al.: Fusion of two malaria vaccine candidate antigens enhances product yield, immunogenicity, and antibody-mediated inhibition of parasite growth in vitro.ImmunoL (2004) 172:6167–6174.
  • MUELLER MS, RENARD A, BOATO F et al.: Induction of parasite growth-inhibitory antibodies by a virosomal formulation of a peptidomimetic of loop I from domain III of Plasmodium faleipation apical membrane antigen 1. Infect. Immun. (2003) 71:4749–4758.
  • THEISEN M, SOE S, BRUNSTEDT K et al.: A Plasmodium falciparum GLURP-MSP3 chimeric protein; expression in Lactococcus lactis, immunogenicity and induction of biologically active antibodies. Vaccine (2004) 22:1188–1198.
  • LUKE TC, HOFFMAN: Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine. J. Exp. Biol. (2003) 206:3803–3808.
  • HURD H, AL-OLAYAN E, BUTCHER GA et al.: In vitro methods for culturing vertebrate and mosquito stages of Plasmodium. Microbes Infect. (2003) 5:321–327.

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.